Remdesivir India Sub-Licensing: Gilead Indicates Conditional Position For Subcontracting

Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.

gilead
Gilead Clarifies Stance On Sub-License Plans For Remdesivir

Remdesivir licensing action may not be over yet, at least based on goings-on in the Indian market.

Gilead Sciences Inc. has now indicated that licensees of the antiviral don’t have a completely free hand to sub-license...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip